Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐TRANSITION PURSUANT TO UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-38623 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 ...

PaySign, Inc. (NASDAQ:PAYS) Q4 2021 Earnings Conference Call March 22, 2022 5:00 PM ET Company Participants Mark Newcomer – Chief Executive Officer Jeff Baker – Chief Financial Officer Conference Call Participants Peter Heckmann – D.A. Davidson Operator Hello, and welcome to the Paysign Fourth Quarter 2021 Earnings Conference Call. As a reminder, this conference is being recorded. This presentation may include forward-looking statements to the extent that the information is presented in this presentation di ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 ...

Financial Data and Key Metrics Changes - The company reported net revenue of $7.8 million for Q3 2021, an increase of $7.9 million year-over-year and a sequential increase of $1.1 million or 16.8% [7] - Adjusted EBITDA for the quarter was $955,000, representing a nearly threefold increase compared to Q2 2021 [7] - Gross margin for the quarter was 51.1%, supported by the conclusion of two pharmaceutical programs [19] - The net loss for the quarter was $271,000, with total operating expenses at $4.2 million [20] Business Line Data and Key Metrics Changes - Plasma revenue accounted for $7 million, up $1.8 million from the same period last year, with an average revenue per month per plasma center of $6,542 [18][22] - Pharma revenue for Q3 2021 was $660,000, an increase of $6 million compared to Q3 2020, driven by changes in accounting estimates [18][23] - The patient affordability vertical saw the launch of three new programs during the quarter, with additional programs expected to launch in Q4 [10][12] Market Data and Key Metrics Changes - Total gross funds loaded increased by 24.7% year-over-year and 7.6% sequentially [8] - Plasma gross funds loaded increased by 42.7% year-over-year and 10.3% from the previous quarter [8] - The company ended the quarter with 359 plasma centers, having onboarded seven additional centers [9][22] Company Strategy and Development Direction - The company aims to bridge gaps left by competitors by leveraging its unique capabilities at the intersection of FinTech and healthcare [15] - Continued investments in patient affordability products and personnel are planned to support growth [12][25] - The company expects to onboard a total of 10 additional plasma centers by the end of the year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth in both plasma and patient affordability segments, despite ongoing challenges from the pandemic [14] - The company anticipates total revenue for the full year to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [27] - Adjusted EBITDA guidance for the full year has been increased to a range of $1.3 million to $1.9 million [27] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt, indicating a solid financial position [26] - Depreciation and amortization expenses are expected to be approximately $2.5 million for the full year [29] Q&A Session Summary - No specific questions or answers were recorded in the provided content, as the call concluded without a Q&A segment [31][32]

1 Transforming What Payments Can Do for You NASDQ: PAYS • 8/5/2021 © 2021 Paysign, Inc. All rights reserved. Paysign® is a registered trademark. ● ● ●● ● ● ● ● yood ● ● ● ● · Who Is Paysign? The content of this document is propriety and confidential information of Paysign, hc. It is not intended to be distributed to any third party without the written consent Thi card sped by Patht: Bank M.A., Nember BDC, prosunt to allense from 1991US A., ht. This ard and ouse exey where Was debt cards re scepted. Use of t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Former name, former address and former fiscal year, if changed since last rep ...

Financial Data and Key Metrics Changes - Total net revenue for Q2 2021 was $6.7 million, a year-over-year increase of 3.2% [7] - Gross margin for the quarter was 47.4%, aided by the end of one pharmaceutical program [17] - Net loss for the quarter was $932,000, with adjusted EBITDA at $219,000, indicating near breakeven performance [18] - Restricted cash grew to $65.8 million during the quarter [18] - Full year revenue guidance is expected to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [26] Business Line Data and Key Metrics Changes - Plasma revenue accounted for $5.9 million or 89% of total revenues, with a year-over-year increase of $1.4 million [17][19] - Pharma revenue decreased to $641,000, down $1.1 million compared to Q2 2020, primarily due to program terminations [21] - Average revenue per month per plasma center was $5,633, with a potential increase to $6,138 if excluding April [19] - The company onboarded 13 additional plasma centers, bringing the total to 356 [10] Market Data and Key Metrics Changes - Total gross funds loaded increased by 34.7% year-over-year, while it decreased by 10.9% from the previous quarter due to seasonality [8] - Purchase volume increased by 44.5% compared to the year-ago period [18] Company Strategy and Development Direction - The company is focusing on diversifying its business and investing for long-term growth, particularly in the patient affordability space [11] - New copay programs are being launched, with five additional programs expected to launch by the end of 2021 [11][22] - The leadership team has been strengthened with new appointments in key positions [12][13] Management's Comments on Operating Environment and Future Outlook - Management noted improving trends in financial results as pandemic-related stimulus measures ended, with expectations for continued improvement [14] - The outlook presumes no re-entry into lockdowns and a recovery in the plasma business as unemployment subsidies end [27] Other Important Information - The company exited the quarter with $6.6 million in unrestricted cash and zero debt [25] - Operating expenses for the full year are expected to increase modestly to $18 million to $18.5 million [27] Q&A Session Summary - No specific questions or answers were documented in the provided content, indicating a conclusion to the call without detailed Q&A interactions [29][30]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) (State or other jurisd ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2021 were $6.3 million, with plasma revenue accounting for $5.4 million or 86% of total revenue, a decrease from $10.6 million in Q1 2020 [18][20] - Gross margin for the quarter was 45.1%, down from 54.1% in the same period last year [19][20] - Adjusted EBITDA for Q1 2021 was a loss of $397,000, compared to a profit of $2.6 million in Q1 2020 [19][20] - The company exited the quarter with $6.6 million in unrestricted cash and zero debt, which is $1.2 million below the December ending balance [25] Business Line Data and Key Metrics Changes - Plasma funds loaded decreased by 2.5% year-over-year and 6.8% sequentially [8] - Plasma revenue was down $2.2 million from the same period last year, with average revenue per plasma center at $5,260 compared to $8,589 last year [22] - Pharma revenue for Q1 2021 was $768,000, a decrease of $2.1 million compared to Q1 2020 [22] Market Data and Key Metrics Changes - First quarter gross dollar volume declined 15.2% year-over-year but increased sequentially by 2.2% [21] - Purchase volume declined 13.1% year-over-year and was unchanged from the previous quarter [21] Company Strategy and Development Direction - The company plans to add a total of 60 new plasma centers in 2021, aiming to exit the year with at least 400 centers [10] - New product offerings in patient affordability are being developed, including a pharmacy claims-based program and a hybrid pharmacy and medical claims-based program [13][14] - The company is focusing on enhancing product features and expanding into other verticals with new digital banking products [15][16] Management's Comments on Operating Environment and Future Outlook - Management noted that Q1 is typically a seasonally weaker quarter due to tax refunds and pandemic-related stimulus payments [7] - The company expects a recovery in business in Q3 2021 as unemployment subsidies are scheduled to end [27] - For the full year 2021, total revenue is expected to be in the range of $29 million to $32 million, reflecting growth of 20% to 32% [26] Other Important Information - The company is seeing positive feedback from the market regarding its product offerings and partnership strategy, which is reflected in its sales pipeline [11] - Significant investments are being made to support business growth and technological capabilities, with depreciation and amortization increasing by 18.6% year-over-year [24] Q&A Session Summary Question: Are there regional differences in plasma business performance due to COVID? - Management indicated no significant regional differences have been observed, with impacts felt across the board [32] Question: What is the plasma revenue guidance for 2022? - Management confirmed that plasma revenue for 2021 is expected to be $27.5 million, with a potential increase to $37.5 million in 2022 [36] Question: Will lawsuit expenses continue? - Management stated that the continuation of lawsuit expenses depends on ongoing issues, with no further details provided [38]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 o TRANSITION PURSUANT TO UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-38623 PAYSIGN, INC. (Exact name of registrant as specified in its charter) Nevada 95-4550154 (State ...